Use of octreotide for prevention of pancreatic leak after pancreatoduodenectomy: study progress

doi:10.16139/j.1007-9610.2022.01.019

Abstract

Abstract:

The pancreatic leak after pancreaticoduodenectomy was one of the main causes of postoperative death, the rate of which remained high. Octreotide, an octapeptide somatostatin analogue, has been used in the prevention and treatment of postoperative pancreatic leak since the 1 990 s. However, octreotide availability was controversial until now. The study on the prevention of pancreatic leak after pancreaticoduodenectomy using octreotide was reviewed in this article.

Key words: Octreotide, Postoperative pancreatic leak, Pancreaticoduodenectomy

CLC Number:

R735.9

XU Yu, ZHANG Junfeng, HUA Rong. Use of octreotide for prevention of pancreatic leak after pancreatoduodenectomy: study progress[J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 83-86.

References 34

[1]	Crist DW, Sitzmann JV, Cameron JL. Improved hospital morbidity, mortality, and survival after the Whipple procedure[J]. Ann Surg, 1987, 206(3):358-365. pmid: 3632096
[2]	Grace PA, Pitt HA, Tompkins RK, et al. Decreased morbidity and mortality after pancreatoduodenectomy[J]. Am J Surg, 1986, 151(1):141-149. pmid: 3946745
[3]	Nassour I, Wang SC, Christie A, et al. Minimally invasive versus open pancreaticoduodenectomy: a propensity-matched study from a national cohort of patients[J]. Ann Surg, 2018, 268(1):151-157. doi: 10.1097/SLA.0000000000002259 URL
[4]	Gleeson EM, Shaikh MF, Shewokis PA, et al. Whipple-ABACUS, a simple, validated risk score for 30-day mortality after pancreaticoduodenectomy developed using the ACS-NSQIP database[J]. Surgery, 2016, 160(5):1279-1287. doi: 10.1016/j.surg.2016.06.040 URL
[5]	Cameron JL, Riall TS, Coleman J, et al. One thousand consecutive pancreaticoduodenectomies[J]. Ann Surg, 2006, 244(1):10-15. doi: 10.1097/01.sla.0000217673.04165.ea pmid: 16794383
[6]	Bassi C, Marchegiani G, Dervenis C, et al. The 2016 update of the International Study Group(ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after[J]. Surgery, 2017, 161(3):584-591. doi: 10.1016/j.surg.2016.11.014 URL
[7]	Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an International Study Group (ISGPF) definition[J]. Surgery, 2005, 138(1):8-13. doi: 10.1016/j.surg.2005.05.001 URL
[8]	Maggino L, Malleo G, Bassi C, et al. Decoding grade B pancreatic fistula: a clinical and economical analysis and subclassification proposal[J]. Ann Surg, 2019, 269(6):1146-1153. doi: 10.1097/SLA.0000000000002673 pmid: 31082914
[9]	Marchegiani G, Andrianello S, Salvia R, et al. Current definition of and controversial issues regarding postope-rative pancreatic fistulas[J]. Gut Liver, 2019, 13(2):149-153. doi: 10.5009/gnl18229 pmid: 30419630
[10]	白雪莉, 沈艺南, 马涛, 等. 有关国际胰腺外科研究组术后胰瘘定义与分级系统(2016版)更新解读与探讨[J]. 中国实用外科杂志, 2017, 37(3):259-261.
[11]	Akgul O, Merath K, Mehta R, et al. Postoperative pancreatic fistula following pancreaticoduodenectomy-stratification of patient risk[J]. J Gastrointest Surg, 2019, 23(9):1817-1824. doi: 10.1007/s11605-018-4045-x URL
[12]	Gaujoux S, Cortes A, Couvelard A, et al. Fatty pancreas and increased body mass index are risk factors of pancreatic fistula after pancreaticoduodenectomy[J]. Surgery, 2010, 148(1):15-23. doi: 10.1016/j.surg.2009.12.005 URL
[13]	Yeo CJ, Cameron JL, Lillemoe KD, et al. Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy?[J]. Ann Surg, 2000, 232(3):419-429. pmid: 10973392
[14]	Ellis RJ, Brock Hewitt D, Liu JB, et al. Preoperative risk evaluation for pancreatic fistula after pancreaticoduodenectomy[J]. J Surg Oncol, 2019, 119(8):1128-1134. doi: 10.1002/jso.25464 pmid: 30951614
[15]	Hackert T, Werner J, Buchler MW. Postoperative pancreatic fistula[J]. Surgeon, 2011, 9(4):211-217. doi: 10.1016/j.surge.2010.10.011 URL
[16]	Hosotani R, Doi R, Imamura M. Duct-to-mucosa pancreaticojejunostomy reduces the risk of pancreatic leakage after pancreatoduodenectomy[J]. World J Surg, 2002, 26(1):99-104. pmid: 11898041
[17]	Adiamah A, Arif Z, Berti F, et al. The use of prophylactic somatostatin therapy following pancreaticoduodenectomy: a meta-analysis of randomised controlled trials[J]. World J Surg, 2019, 43(7):1788-1801. doi: 10.1007/s00268-019-04956-6 pmid: 30798417
[18]	Tewari M, Mahendran R, Kiran T, et al. Outcome of 150 consecutive blumgart’s pancreaticojejunostomy after pancreaticoduodenectomy[J]. India J Surg Oncol, 2019, 10(1):65-71.
[19]	Adachi T, Kuroki T, Kitasato A, et al. Safety and efficacy of early drain removal and triple-drug therapy to prevent pancreatic fistula after distal pancreatectomy[J]. Pancreatology, 2015, 15(4):411-416. doi: 10.1016/j.pan.2015.05.468 URL
[20]	Pessaux P, Sauvanet A, Mariette C, et al. External pancreatic duct stent decreases pancreatic fistula rate after pancreaticoduodenectomy[J]. Ann Surg, 2011, 253(5):879-885. doi: 10.1097/SLA.0b013e31821219af URL
[21]	Büchler M, Friess H, Klempa I, et al. Role of octreotide in the prevention of postoperative complications following pancreatic resection[J]. Am J Surg, 1992, 163(1):125-130. pmid: 1733360
[22]	Gurusamy KS, Koti R, Fusai G, et al. Somatostatin analogues for pancreatic surgery[J]. Cochrane Database Syst Rev, 2013, 4(6):CD008370.
[23]	Bassi C, Butturini G, Molinari E, et al. Pancreatic fistula rate after pancreatic resection. The importance of definitions[J]. Digest Surg, 2004, 21(1):54-59. doi: 10.1159/000075943 URL
[24]	Friess H, Beger HG, Sulkowski U, et al. Randomized controlled multicentre study of the prevention of complications by octreotide in patients undergoing surgery for chronic pancreatitis[J]. Br J Surg, 1995, 82(9):1270-1273. doi: 10.1002/bjs.1800820938 URL
[25]	Montoris M, Zago M, Mosca F, et al. Efficacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections: a prospective, controlled, randomized clinical trial[J]. Surgery, 1995, 117(1):26-31. doi: 10.1016/S0039-6060(05)80225-9 URL
[26]	Adachi T, Kuroki T, Kitasato A, et al. Safety and efficacy of early drain removal and triple-drug therapy to prevent pancreatic fistula after distal pancreatectomy[J]. Pancreatology, 2015, 15(4):411-416. doi: 10.1016/j.pan.2015.05.468 URL
[27]	Adachi T, Ono S, Matsushima H, et al. Efficacy of triple-drug therapy to prevent pancreatic fistulas in patients with high drain amylase levels after pancreaticoduodenectomy[J]. J Surg Res, 2019, 234:77-83. doi: 10.1016/j.jss.2018.08.016 URL
[28]	Li T, D′Cruz RT, Lim SY, et al. Somatostatin analogues and the risk of post-operative pancreatic fistulas after pancreatic resection - A systematic review & meta-analysis[J]. Pancreatology, 2020, 20(2):158-168. doi: 10.1016/j.pan.2019.12.015 URL
[29]	张雷华, 高伟, 侯世方, 等. 应用奥曲肽预防胰十二指肠切除术后胰漏作用的研究[J]. 现代生物医学进展, 2011, 11(12):2282-2285.
[30]	孔瑞, 胡继盛, 李乐, 等. 奥曲肽对胰十二指肠切除术后胰瘘影响的前瞻性研究[J]. 中华外科杂志, 2016, 54(1):21-24.
[31]	El Nakeeb A, Elgawalby A, Ali M, et al. Efficacy of octreotide in the prevention of complications after pancreaticoduodenectomy in patients with soft pancreas and non-dilated pancreatic duct: a prospective randomized trial[J]. Hepatobiliary Pancreat Dis Int, 2018, 17(1):59-63. doi: 10.1016/j.hbpd.2018.01.015 URL
[32]	You DD, Paik KY, Park IY, et al. Randomized controlled study of the effect of octreotide on pancreatic exocrine secretion and pancreatic fistula after pancreatoduodenectomy[J]. Asian J Surg, 2019, 42(2):458-463. doi: 10.1016/j.asjsur.2018.08.006 URL
[33]	Garg PK, Sharma J, Jakhetiya A, et al. The Role of Prophylactic octreotide following pancreaticoduodenectomy to prevent postoperative pancreatic fistula: a meta-analysis of the randomized controlled trials[J]. Surg J, 2018, 4(4):e182-e187. doi: 10.1055/s-0038-1675359 URL
[34]	张鼎, 侍书成, 高运, 等. 奥曲肽预防胰腺切除术后胰瘘及相关并发症的Meta分析[J]. 中华肝胆外科杂志, 2018, 24(6):411-416.